BioSpace News Archive

Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis.

Crescita Therapeutics Inc. announced that the Toronto Stock Exchange has approved the Company’s intention to make a normal course issuer bid for a portion of its common shares as appropriate opportunities arise from time to time.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact

IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced an exclusive distribution agreement with KM Innovations BV, a leading distributor of world-class neurosurgical medical devices and technologies in The Netherlands.

Align Technology, the manufacturer of Invisalign®, allegedly illegally maintaining market dominance

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, will report financial results and business updates for the third quarter and first nine months of 2020 on Monday, November 30, 2020.

Dan Legault, CEO, Antibe Therapeutics Inc., shares his company’s story in an interview with TMX Group.

In a year that has challenged most sectors, including charities, MedicAlert Foundation is delighted to announce that we have been recognized as one of Canada’s Most Admired Corporate Cultures.

Agreement Aims to Help UK Meet its Goal of Diagnosing Three-Quarters of All Cancers at an Early Stage by 2028